Immunomedics (IMMU) Receives Promising Phase II Results for Epratuzumab in Combination with Rituximab and Chemotherapy
More News related to IMMU
- Immunomedics to Present at 51st ASH Annual Meeting
- Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
- Immunomedics to Present at Upcoming Conferences
- Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame
- Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
More News related to Corporate News
- Holly Energy (HEP) Acquires Roadrunner Pipeline from Holly Corp. (HOC); HEP Mentions Enterprise Products (EPD) Transaction
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- UMB Bank (UMBF) Acquires American National Bank Corporate Trust Business
- Center Financial (CLFC) Raises $12.8M In Private Placement
- Markel (MKL) Acquires Majority Interest in Ellicott Dredge Enterprises
Immunomedics, Inc. (Nasdaq: IMMU) today announced that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy for the therapy of patients with newly diagnosed diffuse large B-cell lymphoma produced promising results.
Interim results show that the overall response rate and EFS at 12 months for ER-CHOP, in comparison to R-CHOP, are promising. If the final study analysis on all patients, which should be available by the end of 2008, remains promising, a randomized phase III trial would be needed to definitely assess whether ER-CHOP is more effective than R-CHOP.
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
